Trial Profile
A Phase II Efficacy Trial of Pazopanib in Non-Clear Cell Metastatic Renal Cell Cancer (mRCC) PINCR
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Oct 2023
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Carcinoma; Renal cell carcinoma
- Focus Therapeutic Use
- 28 Sep 2023 Planned End Date changed from 16 Nov 2023 to 16 Nov 2024.
- 27 Apr 2023 Planned End Date changed from 16 May 2023 to 16 Nov 2023.
- 16 Jun 2022 Planned End Date changed from 16 May 2022 to 16 May 2023.